There is no “approved” amyloidosis treatment at this time anywhere in the world to stop the production of the abnormal protein amyloid, which deposits in the organs and tissues in all type of amyloidosis.
Present treatments in AL amyloidosis have been borrowed from those which have been shown to work in myeloma, also a bone marrow disease. If the treatment reduces the production of the “light chains” there is a chance that kidney function may improve.
In AA amyloidosis if the underlying inflammatory disease is successfully controlled the production of the amyloid protein SAA may eventually reduce slowly improving organ function including kidney function.
In both hereditary and wild type ATTR a number of treatments are being trialed to stop the production of the protein in the liver, to stabilize the protein TTR in the blood or to remove the deposited protein in the organs. At this stage TTR stabilizing drugs have been introduced to therapy but these are not available in Australia as yet.
Go to section on the individual types of amyloidosis.